Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome)

Clinical Infectious Diseases

Volumn 22, Issue 6, 1996, Pages 938-943

  Davidson, R N ^a   Di Martino, L ^b   Gradoni, L ^b   Giacchino, R ^b   Gaeta, G B ^b   Pempinello, R ^b   Scotti, S ^b   Cascio, A ^b   Castagnola, E ^b   Maisto, A ^b   Gramiccia, M ^b   Di Caprio, D ^b   Wilkinson, R J ^b   Bryceson, A D M ^b  

^a NORTHWICK PARK HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; LIPOSOME;

ADOLESCENT; ADULT; AGED; AMASTIGOTE; ARTICLE; CELLULAR IMMUNITY; CHILD; FEMALE; HUMAN; INFANT; LEISHMANIA DONOVANI; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS;

EID: 0029743517     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/22.6.938     Document Type: Article

References (22)

1. Gradoni L, Bryceson A, Desjeux P. Treatment of Mediterranean visceral leishmaniasis. Bull World Health Organ 1995;73:191-7.
2. Davidson RN, Di Martino L, Gradoni L, et al. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q J Med 1994;87:75-81.
3. Gradoni L, Davidson RN, Orsini S, Betto P, Giambenedetti M. Activity of liposomal amphotericin B (AmBisome) against Leishmania infantum and tissue distribution in mice. J Drug Target 1993;1:311-6.
4. Thakur CP, Sinha GP, Pandey AK, Barat D, Singh RK. Daily versus alternate-day regimen of amphotericin B in the treatment of kala-azar: a randomized comparison. Bull World Health Organ 1994;72:931-6.
5. Davidson RN, Russo R. Relapse of visceral leishmaniasis in patients who were coinfected with human immunodeficiency virus and who received treatment with liposomal amphotericin B [letter]. Clin Infect Dis 1994;19:560.
6. Evans DA. Leishmania. In: Taylor AER. Baker JR, eds. In vitro methods for parasite cultivation. London: Academic Press, 1987:52-75.
7. Gramiccia M, Gradoni L, Angelici MC. Epidemiology of Mediterranean leishmaniasis caused by Leishmania infantum: isoenzyme and kDNA analysis for the identification of parasites from man, vectors, and reservoirs. In: Hart DT, ed. Leishmaniasis: the current status and new strategies for control. New York: Plenum Press, 1989:21-37.
8. Gradoni L, Scalone A, Gramiccia M. HIV-Leishmania co-infections in Italy: serological data as an indication of the sequence of acquisition of the two infections. Trans R Soc Trop Med Hyg 1993;87:94-6.
9. Gramiccia M, Gradoni L, di Martino L, Romano R, Ercolini D. Two syntopic zymodemes of Leishmania infantum cause human and canine visceral leishmaniasis in the Naples area, Italy. Acta Tropica (Basel) 1992;50:357-9.
10. Giacchino R, Giambartolomei G, Tasso L, et al. Treatment with liposomal amphotericin B of a child affected with drug-resistant visceral leishmaniasis. Trans R Soc Trop Med Hyg 1993;87:310.
11. Smith OP, Hann IM, Cox H, Novelli V. Visceral leishmaniasis: rapid response to AmBisome treatment. Arch Dis Child 1995;73:157-9.
12. Di Martino L, Raimondi F, Scotti S, Davidson RN. Gradoni L, Giacchino R. Efficacy and tolerability of liposomal amphotericin B in Italian infants with visceral leishmaniasis. Trans R Soc Trop Med Hyg 1993;87:477.
13. Gradoni L, Gaeta GB, Pellizzer G, Maisto A, Scalone A. Mediterranean visceral leishmaniasis in pregnancy. Scand J Infect Dis 1994;26:627-9.
14. Seaman J, Boer C, Wilkinson R, de Jong J, de Wilde E, Sondorp E, Davidson R. Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clin Infect Dis 1995;21:188-93.
15. Janknegt R, de Marie S, Bakker-Woudenberg IAJM, Crommelin DJA. Liposomal and lipid formulations of amphotericin B: clinical pharmacokinetics. Clin Pharmacokinet 1992;23:279-91.
16. Dietze R, Milan EP, Berman JD, et al. Treatment of Brazilian kala-azar with a short course of Amphocil (amphotericin B cholesterol dispersion). Clin Infect Dis 1993;17:981-6.
17. Dietze R, Fagundes SMS, Brito EF, et al. Treatment of kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days. Trans R Soc Trop Med Hyg 1995;89:309-11.
18. Llanos-Cuentas A, Echevarria J, Chang J, et al. Randomized trial of amphotericin B complex (ABLC) versus Fungizone (F) in patients with mucocutaneous leishmaniasis [abstracts no We01-7]. In: Proceedings and abstracts of the 13th International Congress for Tropical Medicine and Malaria (Jomtien, Pattaya, Thailand). Bangkok: Faculty of Tropical Medicine, Mahidol University, 1992.
19. Gokhale PC, Kshirsagar NA, Khan MU, et al. Successful treatment of resistant visceral leishmaniasis with liposomal amphotericin B. Trans R Soc Trop Med Hyg 1994;88:228.
20. Thakur CP. Comparison of glucose versus fat emulsion in the preparation of amphotericin B for use in kala-azar. Trans R Soc Trop Med Hyg 1994;88:698-9.
21. Mishra M, Biswas UK, Jha AM, Khan AB. Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar. Lancet 1994;344:1599-600.
22. Thakur CP, Sinha GP, Barat D, Singh RK. Are incremental doses of amphotericin B required for the treatment of visceral leishmaniasis? Ann Trop Med Parasitol 1994;88:365-70.